EPA-Based Composition for RLP-C Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases, particularly those related to high blood pressure, coronary heart disease, and atherosclerotic cardiovascular disease, are inadequate in effectively reducing remnant-like particle cholesterol (RLP-C) levels, which are associated with increased risk of atherosclerotic cardiovascular disease.
Innovation Solution
Administration of a pharmaceutical composition comprising eicosapentaenoic acid (EPA) or its derivatives, specifically ethyl eicosapentaenoate, at doses of about 1 g to 4 g per day, with minimal to no docosahexaenoic acid (DHA), to subjects with cardiovascular-related diseases, including those on statin therapy, to lower triglycerides and RLP-C levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cardiovascular diseases are used, then general cardiovascular risk is addressed, but RLP-C levels are not effectively reduced
Solution Approach 1:
The patent applies parameter changes by administering EPA at specific dosage ranges (1-4 g per day) to achieve significant reduction in RLP-C levels (10-75%). This quantitative parameter adjustment transforms the treatment effectiveness for this specific lipid parameter without compromising other cardiovascular risk factors.
2Reliability
If EPA is administered at high doses (2-4 g per day), then RLP-C and triglyceride levels are significantly reduced, but the complexity of dosing regimen increases
Solution Approach 1:
The patent achieves multi-functionality by using EPA to simultaneously reduce multiple atherogenic parameters including RLP-C, triglycerides, and LDL-C levels. This single agent addresses multiple cardiovascular risk factors, simplifying the overall treatment approach despite the specific dosing requirements.
Data Source
AI summary
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.